SCM
ARQT icon

Sio Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Sio Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-159,626
Closed -$1.48M – 43
2024
Q2 		$1.48M Sell
159,626
-476,343
-75% -$4.31M 0.4% 34
2024
Q1 		$6.3M Hold
635,969
– – 1.88% 14
2023
Q4 		$2.05M Hold
635,969
– – 0.47% 25
2023
Q3 		$3.38M Buy
635,969
+342,922
+117% +$2.92M 1.05% 29
2023
Q2 		$2.79M Buy
+293,047
New +$3.25M 0.71% 27

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sio Capital Management's ARQT Position: Q3 2024 in Review

Sio Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q3 2024, closing a stake of 159,626 shares — an estimated $1.48M sold.

Sio Capital Management first reported a position in ARQT in Q2 2023 and held it in 5 quarters. The position peaked at $6.3M in Q1 2024. 188 funds tracked by Wall St. Rank hold ARQT as of Q3 2024.

  • Sio Capital Management reported no remaining Arcutis Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Sio Capital Management sold 159,626 Arcutis Biotherapeutics shares in Q3 2024, an estimated $1.48M.
  • Sio Capital Management first reported a position in Arcutis Biotherapeutics in Q2 2023 and held it in 5 quarters.
  • Sio Capital Management's Arcutis Biotherapeutics position peaked at $6.3M in Q1 2024.
  • 188 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2024.

Based on Sio Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.